{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:19:45Z","timestamp":1760296785294},"reference-count":35,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>TAK-457 is an injectable prodrug of TAK-456, which is a novel oral triazole compound with potent antifungal activity. The in vivo efficacy of TAK-457 was evaluated in two models of invasive pulmonary aspergillosis with CDF<jats:sub>1<\/jats:sub>mice and CBA\/J mice with transient neutropenia induced by cyclophosphamide. Against the infection in CDF<jats:sub>1<\/jats:sub>mice, treatment with 10 mg of TAK-457 and 1 mg of amphotericin B\/kg reduced the fungal burden in lungs and rescued all mice. In the infection model with CBA\/J mice, TAK-457 at a dose of 10 mg\/kg significantly prolonged the survival time of mice, showing significant reduction of lung chitin levels and the plasma \u03b2-<jats:sc>d<\/jats:sc>-glucan levels. On the other hand, amphotericin B at 1 mg\/kg which was a maximum tolerable dose showed slight but not significant prolongation of survival time of mice, although it also reduced the lung chitin levels and the plasma \u03b2-<jats:sc>d<\/jats:sc>-glucan levels to a lower extent but still significantly. These results suggest that TAK-457 is a promising candidate for development for the treatment of invasive aspergillosis in humans.<\/jats:p>","DOI":"10.1128\/aac.46.2.283-287.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"283-287","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of TAK-457, a Novel Intravenous Triazole, against Invasive Pulmonary Aspergillosis in Neutropenic Mice"],"prefix":"10.1128","volume":"46","author":[{"given":"Ryogo","family":"Hayashi","sequence":"first","affiliation":[{"name":"Pharmacology Research Laboratories II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Kitamoto","sequence":"additional","affiliation":[{"name":"Pharmacology Research Laboratories II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Iizawa","sequence":"additional","affiliation":[{"name":"Pharmacology Research Laboratories II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Itoh","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories I"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Kitazaki","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Okonogi","sequence":"additional","affiliation":[{"name":"Research Management Department, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/313445"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.22.100168.000511"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF01964057","volume":"8","year":"1989","unstructured":"Bodey, G. P., and S. Vartivarian. 1989. Aspergillosis. Eur. J. Clin. Infect. Dis.8:413\u2013437.","journal-title":"Eur. J. Clin. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.2165\/00003495-200161001-00004","volume":"61","year":"2001","unstructured":"Boogaerts, M., and J. Maertens. 2001. Clinical experience with itraconazole in fungal infections. Drugs61:S39\u2013S47.","journal-title":"Drugs"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.981-985.2001"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.4049\/jimmunol.163.11.6086","volume":"163","year":"1999","unstructured":"Borna, M., R. M. Strieter, T. A. Moore, W. C. Tsai, S. A. Lita, and T. A. Standiford. 1999. CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defence in invasive pulmonary aspergillosis. J. Immunol.163:6086\u20136094.","journal-title":"J. Immunol."},{"key":"e_1_3_2_8_2","first-page":"113","volume":"71","year":"1994","unstructured":"Curtis, L. J., G. B. Huffnagle, G.-H. Chen, M. L. Warnock, M. R. Gyetko, R. A. McDonald, P. J. Scott, and G. B. Toews. 1994. Experimental murine pulmonary cryptococcosis. Lab. Investig.71:113\u2013126.","journal-title":"Lab. Investig."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/513943"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.6.1147"},{"key":"e_1_3_2_11_2","first-page":"27","volume":"6","year":"1991","unstructured":"Elstad, M. R. 1991. Aspergillosis and lung defenses. Semin. Respir. Infect.6:27\u201336.","journal-title":"Semin. Respir. Infect."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/BF01964056","volume":"8","year":"1989","unstructured":"Graybill, J. R. 1989. New antifungal agents. Eur. J. Clin. Infect. Dis.8:402\u2013412.","journal-title":"Eur. J. Clin. Infect. Dis."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1248\/cpb.48.1947","volume":"48","year":"2000","unstructured":"Ichikawa, T., T. Kitazaki, Y. Matsushita, H. Hosono, M. Yamada, M. Mizuno, and K. Itoh. 2000. Optically active antifungal azoles. XI. An alternative synthetic route for 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazole-1-yl) phenyl]-2-imidazolidinone (TAK-456) and its analog. Chem. Pharm. Bull.48:1947\u20131953.","journal-title":"Chem. Pharm. Bull."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1248\/cpb.49.1102","volume":"49","year":"2001","unstructured":"Ichikawa, T., T. Kitazaki, Y. Matsushita, M. Yamada, R. Hayashi, M. Yamaguchi, Y. Kiyota, K. Okonogi, and K. Itoh. 2001. Optically active antifungal azoles. XII. Synthesis and antifungal activity of the water-solubleprodrugs of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazole-1-yl)-propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone. Chem. Pharm. Bull.49:1102\u20131109.","journal-title":"Chem. Pharm. Bull."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1348-0421.1988.tb01451.x","volume":"32","year":"1988","unstructured":"Iizawa, Y., T. Nishi, M. Kondo, and A. Imada. 1988. Experimental chronic pulmonary infection in mice caused by Klebsiella pneumoniae. Microbiol. Immunol.32:895\u2013906.","journal-title":"Microbiol. Immunol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1093\/clinids\/19.Supplement_1.S41","volume":"19","year":"1994","unstructured":"Khoo, S. H., and D. W. Denning. 1994. Invasive aspergillosis in patients with AIDS. Clin. Infect. Dis.19(Suppl. 1):S41\u2013S48.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1248\/cpb.48.1935","volume":"48","year":"2000","unstructured":"Kitazaki, T., T. Ichikawa, A. Tasaka, H. Hosono, Y. Matsushita, R. Hayashi, K. Okonogi, and K. Itoh. 2000. Optically active antifungal azoles. X. Synthesis and antifungal activity of N-[4-(azolyl)phenyl]- and N-[4-(azolylmeth-yl)phenyl]-N\u2032-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-azolones. Chem. Pharm. Bull.48:1935\u20131946.","journal-title":"Chem. Pharm. Bull."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.12.5.987-992.1975"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.3.397"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jcla.1860090208","volume":"9","year":"1995","unstructured":"Mitsutake, K., S. Kohno, T. Miyazaki, Y. Yamamoto, K. Yanagihara, H. Kakeya, A. Hashimoto, H. Koga, and K. Hara. 1995. Detection of (1\u20133)-\u03b2-d-glucan in a rat model of aspergillosis. J. Clin. Lab. Anal.9:119\u2013122.","journal-title":"J. Clin. Lab. Anal."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.12.3115-3118.1995"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.42.11.3018","volume":"42","year":"1998","unstructured":"Mnavathu, E. K., J. L. Cutright, and P. H. Chandrasekar. 1998. Organism-dependent fungicidal activities of azoles. Antimicrob. Agants Chemother.42:3018\u20133021.","journal-title":"Antimicrob. Agants Chemother."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.27.2.376-386.1980"},{"key":"e_1_3_2_24_2","unstructured":"National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard. Document M38-P. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91152-9"},{"key":"e_1_3_2_26_2","first-page":"779","volume":"42","year":"1998","unstructured":"Petit, C., M. Ch\u00e9ron, V. Joly, J. M. Rodrigues, J. Bolard, and F. Gaboriau. 1998. In vivo therapeutic efficacy in experimental murine mycoses of a new formulation deoxycholate-amphotericin B obtained by mild heating. J. Antimicrob. Chemother.42:779\u2013785.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_27_2","first-page":"S12","volume":"36","year":"1998","unstructured":"Roilides, E., M. C. Dignani, E. J. Anaissie, and J. H. Rex. 1998. The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med. Mycol.36:S12\u2013S25.","journal-title":"Med. Mycol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/jac\/42.5.635","volume":"42","year":"1998","unstructured":"Sandeep, S., J. A. Khan, and P. C. Ghosh. 1998. Toxicity and therapeutic efficacy of amphotericin B derivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis. J. Antimicrob. Chemother.42:635\u2013642.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.1.77"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/02681218980000021","volume":"27","year":"1989","unstructured":"Spredbury, C. L., T. Krausz, S. Pervez, and J. Cohen. 1989. Invasive aspergillosis: clinical and pathological features of a new animal model. J. Med. Vet. Mycol.27:5\u201315.","journal-title":"J. Med. Vet. Mycol."},{"key":"e_1_3_2_31_2","first-page":"S221","volume":"12","year":"1989","unstructured":"Stein, D. K., and A. M. Sugar. 1989. Fungal infection in the immunocompromised host. Diagn. Microbiol. Infect. Dis.12(Suppl. 4):S221\u2013S228.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1520"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-4453(97)80010-2","volume":"34","year":"1997","unstructured":"Tumbarello, M., E. Tacconelli, L. Pagano, E. O. La Barbera, G. Morace, R. Cauda, G. Leone, and L. Ortona. 1997. Comparative analysis of prognostic indicators of aspergillosis in haematological malignancies and HIV infection. J. Infect.34:55\u201360.","journal-title":"J. Infect."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.540-545.2000"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/317451"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.2.283-287.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.2.283-287.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T15:59:43Z","timestamp":1682265583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.2.283-287.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1128\/AAC.46.2.283-287.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.2.283-287.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]},"assertion":[{"value":"2001-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}